Novanta Inc. Announces \$1.45 Billion Acquisition of Riverpoint Medical
Overview and Strategic Rationale
Novanta Inc. (NASDAQ: NOVT), a leading technology partner to global medical and industrial OEMs, has entered into a definitive agreement to acquire Riverpoint Medical, a category leader in minimally invasive surgical consumables, from Arlington Capital Partners. The transaction is valued at \$1.2 billion in upfront cash, with an additional milestone payment of \$250 million expected in Q1 2027, bringing the total potential consideration to \$1.45 billion. The deal is expected to close in Q3 2026, subject to regulatory approvals and customary closing conditions.
- Accelerates Novanta’s strategic direction: Expands portfolio into high-growth minimally invasive surgery segment.
- Doubles recurring medical consumables revenue: Projected to reach approximately \$300 million post-acquisition.
- Deepens medical end-market concentration: Medical revenue will represent 60% of Novanta’s total revenue after the deal.
- Immediate accretion: Expected to be immediately accretive to revenue growth, margins, adjusted diluted EPS, and operating cash flows.
- Significant addressable market expansion: Adds an estimated \$2 billion in addressable market opportunity.
Financial and Operating Impact
Valuation: The upfront purchase price of \$1.2 billion represents approximately 19x Riverpoint’s estimated 2026 Adjusted EBITDA excluding synergies, or approximately 17x including year-5 pro forma synergies.
Synergies: Novanta expects more than \$80 million in cumulative profit and cash flow synergies over five years. Riverpoint is projected to generate Adjusted EBITDA (including synergies) of roughly \$80 million in 2027.
Financing: The acquisition will be funded via cash on hand, Novanta’s existing credit facility, and a recently completed \$300 million equity raise.
Leverage: Net leverage ratio anticipated at 2.7x post-closing (less than 3.0x gross), with a target to reduce net leverage below 2.3x by year-end 2027.
- Accretion: Immediately accretive to adjusted diluted EPS in 2026; accretive to revenue growth, margins, and cash flows in 2027.
- Guidance: Novanta confirms its standalone Q2 and FY2026 guidance; updates for Riverpoint will be provided post-closing.
About Riverpoint Medical
Riverpoint Medical is a notable developer and manufacturer of advanced surgical fibers and related technologies, serving OEMs with private-label minimally invasive surgical consumables and instruments. Its portfolio includes unique implants, complex assemblies, and IP-protected coatings for implant materials, with applications primarily in sports medicine, trauma, and cardiovascular surgery.
- Growth: Riverpoint’s revenue and cash flows are growing at twice the rate of Novanta, with an expected long-term annual revenue growth outlook of 12% to 15%.
- Manufacturing footprint: Riverpoint’s manufacturing is FDA-registered in Portland, Oregon, and San Jose, Costa Rica, improving supply chain resilience and responsiveness.
- Innovation: Proprietary material science and coating technologies, including osteoconductive materials. Ability to handle 510(k) clearance end-to-end for customers.
Leadership Commentary
“Riverpoint Medical is an exceptional business, a market leader in high-growth minimally invasive surgical consumables that is perfectly aligned with our strategic direction and business model,” said Matthijs Glastra, Chair and CEO of Novanta. “Together, this acquisition is projected to double our recurring medical consumables revenue, deepen our medical end-market concentration, and meaningfully accelerate revenue and profit growth. Riverpoint is the right fit, at the right time, and Novanta is the right owner.”
Doug King, CEO of Riverpoint Medical, added: “Joining Novanta will accelerate our strategy, while giving our customers access to a broader suite of surgical solutions through a single, deeply trusted OEM partner. We are thankful to Arlington for their strong partnership and excited about the opportunities Novanta will provide our team going forward.”
Advisors
- Baird and J.P. Morgan Securities LLC: Financial advisors to Novanta.
- Ropes & Gray LLP and King & Spalding LLP: Legal advisors to Novanta.
- Jefferies LLC: Sole financial advisor to Riverpoint Medical.
- Goodwin Procter LLP: Legal advisor to Riverpoint Medical.
Conference Call
Novanta will host a conference call on June 9, 2026 at 8:30 a.m. ET to discuss the acquisition. Investors can call (888) 346-3959 or access the webcast on Novanta’s website. A replay will be available until September 8, 2026.
Risks and Considerations for Shareholders
- Deal Completion Risks: The transaction is subject to regulatory approvals and closing conditions, which may cause delays or prevent completion.
- Integration Risks: There is a risk that Riverpoint Medical may not be integrated successfully or synergies may not be realized as expected.
- Impact on Personnel and Customer Relationships: The deal announcement may affect Riverpoint Medical’s ability to retain key personnel and maintain relationships with business partners and customers.
- Leverage and Financing Risks: The acquisition increases Novanta’s leverage; successful reduction depends on future cash flow performance.
- Forward-Looking Statements: Many expectations are based on current assumptions and may be impacted by unforeseen events.
- Non-GAAP Measures: Adjusted EBITDA, Adjusted Gross Margin, and Adjusted Diluted EPS referenced in the release are non-GAAP and may differ from actual GAAP results.
About Novanta and Arlington Capital Partners
Novanta: A global supplier of core technology solutions for medical, life science, and industrial OEMs, with expertise in precision medicine, manufacturing, robotics, and automation. Common shares are quoted on Nasdaq as “NOVT”.
Arlington Capital Partners: A Washington, D.C.-area private investment firm focused on government-regulated industries, including healthcare. Arlington has invested in over 200 companies and raised over \$14 billion in committed capital.
Investor Contact
For further information, contact Ray Nash, Novanta Investor Relations, at (781) 266-5137 or [email protected].
Disclaimer: This article contains forward-looking statements, which are subject to risks and uncertainties. Actual results may differ materially from those anticipated. Investors should not rely solely on this article for investment decisions and are encouraged to review official filings and disclosures. Novanta disclaims any obligation to update these statements except as required by law.
